The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M05 | Drugs for treatment of bone diseases | |
| 3 | M05B | Drugs affecting bone structure and mineralization | |
| 4 | M05BA | Bisphosphonates | |
| 5 | M05BA08 | Zoledronic acid |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 4 mg |
| Active Ingredient | Description | |
|---|---|---|
| Zoledronic acid |
Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZERLINDA Solution for infusion | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| ZOBONE Concentrate for solution for infusion | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| ZOLEDRONIC ACID HOSPIRA 4mg/100ml Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ZOLEDRONIC ACID HOSPIRA 5mg/100ml Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
